| Montelukast Zafirlukast |
CysLTR1 antagonists |
Both are FDA and EMA approved for treatment of asthma |
Studies show improvement in upper and lower airway symptoms |
31, 32
|
| Zileuton |
5-lipoxygenase inhibitor |
FDA approved for treatment of asthma |
Requires monitoring of transaminases, all cases of hepatotoxicity resolved after discontinuation of medication |
34, 35, 36, 37
|
| Omalizumab |
Binds free IgE |
FDA and EMA approved |
A study in patients with nasal polyps showed decrease in the total nasal endoscopic score |
37, 38, 39
|
| Prasugrel |
P2Y12 receptor antagonist |
FDA approved for acute coronary syndrome; Phase II for AERD |
Under investigation in AERD to determine if it attenuates severity of aspirin reactions |
NCT01597375 |
| Ifetroban |
TP receptor antagonist |
Phase II |
Under investigation in AERD to determine if it attenuates severity of aspirin reactions |
NCT02216357 |
| ARRY-502 |
CRTH2 antagonists |
Phase II |
Not yet studied in AERD |
|
| AZD1981 |
| QAW039 |
| OC000459 |
| Mepolizumab |
Blocks IL-5 |
Phase II/III |
Has been studied in asthma, recently completed study in nasal polyps |
52, NCT01362244
|
| Dupilumab |
Blocks IL-4Rα |
Phase II |
Has been studied in asthma, recently completed study in nasal polyps |
NCT01920893 |
